No Data
Express News | Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic Adi Platform, Advancing Toward First-in-Human Clinical Trials
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement With Aditxt, Inc.
Appili Therapeutics Inc: INTERIM MDA EN
Appili Therapeutics Inc: INTERIM FINANCIAL STATEMENTSREPORT EN
Express News | Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Express News | Aditxt Provides Update on Equity Line of Credit, Atm Usage, and Outstanding Number of Shares